海创药业-U
            
                (688302)
        
        
        
        
            
                | 流通市值:47.73亿 |   |   | 总市值:47.73亿 | 
| 流通股本:9901.56万  |   |   | 总股本:9901.56万  | 
            
        
        
     
 
  
    
    
      
            
      
         
        
        
          | 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 
| 公司类型 | 通用 | 通用 | 通用 | 通用 | 
| 一、营业总收入 | 23,351,806.02 | 13,167,136.01 | - | 366,836.28 | 
|   营业收入 | 23,351,806.02 | 13,167,136.01 | - | 366,836.28 | 
| 二、营业总成本 | 142,363,467.94 | 85,364,215.91 | 36,727,239.36 | 217,539,778.96 | 
|   营业成本 | 100,984.3 | 62,643.88 | - | 335,918 | 
|   税金及附加 | 647,342.45 | 376,732.29 | 86,848.79 | 411,284.78 | 
|   销售费用 | 25,686,625.67 | 10,500,524.53 | 3,901,495.5 | 11,353,420.85 | 
|   管理费用 | 32,376,189.72 | 21,421,965.73 | 10,121,852.82 | 42,140,341.42 | 
|   研发费用 | 88,764,019.99 | 56,967,171.91 | 24,765,858.75 | 174,031,725.15 | 
|   财务费用 | -5,211,694.19 | -3,964,822.43 | -2,148,816.5 | -10,732,911.24 | 
|   其中:利息费用 | 279,129.96 | 195,045.1 | 205,515.51 | 526,607.32 | 
|   其中:利息收入 | 6,614,737.69 | 4,571,463.99 | 2,456,849.16 | 10,013,732.89 | 
| 三、其他经营收益 |  |  |  |  | 
|   加:公允价值变动收益 | 5,326,709.35 | 2,054,220.43 | 1,535,554.13 | 3,962,834.76 | 
|   加:投资收益 | 3,055,541.53 | 1,843,351.3 | 1,920,474.11 | 9,144,656.32 | 
|   信用减值损失(新) | -890,020.49 | -806,540.25 | -731,402.59 | -324,710.27 | 
|   其他收益 | 12,971,810.91 | 7,494,467.56 | 1,902,857.49 | 4,908,617.33 | 
| 四、营业利润 | -98,547,620.62 | -61,611,580.86 | -32,099,756.22 | -199,481,544.54 | 
|   加:营业外收入 | - | - | - | 110 | 
|   减:营业外支出 | 596,494.84 | 239,605.3 | - | 2,073.6 | 
| 五、利润总额 | -99,144,115.46 | -61,851,186.16 | -32,099,756.22 | -199,483,508.14 | 
|   减:所得税费用 | 3,048.94 | 2,014.8 | 2,012.55 | 12,227.96 | 
| 六、净利润 | -99,147,164.4 | -61,853,200.96 | -32,101,768.77 | -199,495,736.1 | 
| (一)按经营持续性分类 |  |  |  |  | 
|   持续经营净利润 | -99,147,164.4 | -61,853,200.96 | -32,101,768.77 | -199,495,736.1 | 
| (二)按所有权归属分类 |  |  |  |  | 
|   归属于母公司股东的净利润 | -99,147,164.4 | -61,853,200.96 | -32,101,768.77 | -199,495,736.1 | 
|   扣除非经常损益后的净利润 | -119,904,731.35 | -73,005,634.95 | -37,460,654.5 | -217,509,880.91 | 
| 七、每股收益 |  |  |  |  | 
|   (一)基本每股收益 | -1 | -0.62 | -0.32 | -2.01 | 
| 八、其他综合收益 | -69,763.02 | -39,554.47 | -12,510.77 | -139,265.41 | 
|   归属于母公司股东的其他综合收益 | -69,763.02 | -39,554.47 | -12,510.77 | -139,265.41 | 
| 九、综合收益总额 | -99,216,927.42 | -61,892,755.43 | -32,114,279.54 | -199,635,001.51 | 
|   归属于母公司股东的综合收益总额 | -99,216,927.42 | -61,892,755.43 | -32,114,279.54 | -199,635,001.51 | 
| 公告日期 | 2025-10-31 | 2025-08-14 | 2025-04-26 | 2025-04-19 | 
| 审计意见(境内) |  |  |  | 标准无保留意见 |